Inactive Instrument

Almirall SA Stock CBOE EUROPE EQUITIES

Equities

ES0157097017

Pharmaceuticals

End-of-day quote CBOE EUROPE EQUITIES
- EUR - Intraday chart for Almirall SA

Financials

Sales 2024 * 971M 1.05B 1.43B Sales 2025 * 1.07B 1.15B 1.58B Capitalization 1.82B 1.96B 2.68B
Net income 2024 * 25M 26.9M 36.82M Net income 2025 * 62M 66.72M 91.3M EV / Sales 2024 * 1.79 x
Net cash position 2024 * 81.01M 87.17M 119M Net cash position 2025 * 115M 123M 169M EV / Sales 2025 * 1.59 x
P/E ratio 2024 *
84.4 x
P/E ratio 2025 *
30.3 x
Employees -
Yield 2024 *
2.15%
Yield 2025 *
2.18%
Free-Float 34.78%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 14-07-24
Director of Finance/CFO 54 19-11-10
Chief Tech/Sci/R&D Officer - 21-07-06
Members of the board TitleAgeSince
Director/Board Member 81 07-05-28
Director/Board Member - 15-12-31
Director/Board Member 65 20-06-30
More insiders
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
More about the company